Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Research in Brief

This article was originally published in The Gray Sheet

Executive Summary

Enrollment ends for Boston Sci’s latest Watchman trial; Edwards, MicroVention studies begin.

You may also be interested in...

Research In Brief

Data updates from HRS, SCAI meetings, and more.

New Products In Brief

Boston Scientific becomes the first with drug-eluting stents that are FDA-approved for use in patients experiencing a heart attack. More product news.

Left Atrial Appendage Closure Studies: FDA Offers Tips

The clinical path toward FDA approval of a left atrial appendage closure system for preventing stroke in atrial fibrillation patients has not been simple so far, informing the agency’s current expectations.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts